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ABSTRACT 
Diabetes can not be cured completely. Incidence of diabetes mellitus increasing day by day. Synthetic drugs which are used fo r the treatment of 
diabetes have many side effects and frequency of dosing is more. To overcome such problems novel carrier system has been chose. Herbal 
extracts have been widely accepted as the potential medicines with less side effects as compared to synthetic drug molecules.  Biodegradable 
polymers are having wide use for the preparation of vesicular system to control the drug release pattern of drugs. “Polymeric microparticles” 
considered as novel carrier technique to control the release of herbal plant extracts from vesicular system. Extraction of crude drug (Glycyrrhiza 
glabra) done with successive solvent extraction method by using different solvents like Petroleum ether, ethyl acetate, chloroform, methanol, 
and ethanol. In phytochemical screening we found different constituents but glycyrrhizin which is active constituent of roots, which have anti-
hyperglycemic effect. Polymeric microparticles formulated with emulsification method. After characterization the microparticles shows good 
results of drug release and entrapment efficiency. In the current research work micoparticles has been developed of chitosan employed to 
enhance the drug release. Polymeric micopartcles were characterized and evaluated for antidiabetic activity. Glycyrrhiza glabra decrease the 
blood glucose level in albino rats. 
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INTRODUCTION: 
Yastimadhu (Glycyrrhiza glabra) is another Indian medicinal 
plant, which has enormous traditional values against various 
diseases and many bioactive compounds have been isolated 
from this plant. 
Objective: 
The objective of present research work was to control the 
drug release from carrier system and to reduce the side 
effects related with the use of synthetic drug molecules. 
Dosing frequency was the another drawback of conventional 
drug delivery system, to overcome by this we used sustained 
release dosage form and extracted anti-diabetic agents from 
herbal origin then encapsulated in polymeric microparticles. 
MATERIAL AND METHODS: 
Roots of Yastimadhu (Glycyrrhiza glabra) were collected 
from agriculture college, Indore. Their identification and 
authentification was confirmed by Department of Botany, 
Holkar Science College, Indore. The roots were collected, 
washed well to remove all the dirt and were shade dried and 
then powdered transferred into airtight containers with 
proper labeling for future use. 
Preparation of plant extract: 
Petroleum ether Extract: 
The coarsely powdered, dried plant parts (50 g) were 
extracted with 300 ml -500 ml petroleum ether by hot 
extraction process (soxhlet) for 4 hours. After completion of 
extraction the solvent was removed by distillation and 
concentrated in vacuum. 
Chloroform Extract: 
The marc left after petroleum ether extraction was dried and 
extracted with 300 ml -500 ml chloroform by hot extraction 
process (soxhlet) for 4 hours. After completion of extraction 
the solvent was removed by distillation and concentrated in 
vacuo. 
Ethyl acetate Extract: 
The marc left after the extraction of the chloroform 
extraction was dried and extracted with 300 ml -500 ml ethyl 
acetate by hot extraction process (soxhlet) for 4 hours. After 
completion of extraction the solvent was removed by 
distillation and concentrated in vacuo. 
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Methanol Extract: 
The marc left after the ethyl acetate extraction was dried and 
extracted with 300 ml -500 ml methanol by hot extraction 
process (soxhlet) for 4 hours. After completion of the 
extraction the solvent was removed by distillation and 
concentrated in vacuo. 
Ethanol Extract: 
The marc left after the methanol extraction was dried and 
extracted with 300 ml -500 ml ethanol by hot extraction 
process (soxhlet) for 4 hours. After completion of the 
extraction the solvent was removed by distillation and 
concentrated in vacuo. 
The above extracts were used for phytochemical studies. The 
extractive values for each extract were calculated and 
recorded.  
 
 
 
 
Table1: Successive extractive values of the powdered roots 
of Glycyrrhiza glabra 
S. No. Extracts 
Yield 
(% W/W) 
1. Petroleum Ether Extract 3.12 
2. Chloroform Extract 2.43 
3. Ethyl acetate Extract 3.01 
4. Methanol Extract 3.37 
5. Ethanol Extract 4.11 
 
 
Figure 1: UV spectra of isolated Glycyrrhizin
 
 
Figure 2: HPLC spectra of isolated Glycyrrhizin 
 
Pharmaceutical screening of active constituent: 
1. Acute Toxicity study: The acute toxicity study is use to 
establish the therapeutic index, i.e. the ratio between 
the pharmacologically effective dose and lethal dose on 
the same strain and species (LD50/ED50). The animals 
were divided into four groups and each group 
consisted of five mice. The defined or fixed dose level of 
aqueous and ethanolic extracts (2000 mg/kg) were 
given orally to identify a dose producing evident 
toxicity. The animals were observed continuously for 2 
hours for behavioral, neurological and autonomic 
profiles. The toxicity signs were observed after 24 
hours till fourteen days for any lethality or death.
 
Table 2: Result of acute toxicity study of Glycyrrhizin: 
S.No. Group No. of 
animal used 
Treatment 
Dose (mg/kg) body wt. 
No. of animals recovered after study 
24 hrs. 72 hrs. 14 days 
1 Group A 
(Alcoholic Extract) 
5 2000 5 5 4 
2 Group B 
(Aqueous Extract) 
5 2000 5 5 4 
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2. Oral Glucose Tolerance Test: Animals were divided 
in nine groups and each group consisted of six rats. 
Overnight fasted rats were used for study. 
Group I:   Normal control rats administered saline (0.9% 
w/v);  
Group II: Diabetic rats administered standard drug 
Glibenclamide (2.5 mg / kg) daily 
Group III: Diabetic rats administered test sample (50 
mg/kg);  
Group IV: Diabetic rats administered test sample (100 
mg/kg); 
 
Table 3: Effect of Glycyrrhizin from Glycyrrhya glabra on oral glucose tolerance test in rats 
S. No. Treatment 
n=6 
Fasting blood glucose level (mg / dl) 
0 min 30 min 60 min 120 min 
1 Normal  91.42± 0.92 132.33± 1.12  117.29± 1.11 111.03± 1.17 
2 
Standard  
(Glibenclamide,  
2.5mg/kg)  
94.01± 0.73 110.33±0.56*   83.09 ± 0.97* 79.39± 0.05* 
3 
Glycyrrhizin 
(50mg/kg,)   
98.01± 1.32 113.33±1.48*  102.67±0.92*  90.01± 0.37* 
4 
Glycyrrhizin 
(100mg/kg)  
104.09±1.67* 125.04±1.46  104.31±1.87*  91.83± 2.11* 
Normal Control- Vehicle 10 ml/kg, Reading are values ± S.E.M, 
 n = Numbers of animals in each group 
* P < 0.05 v/s Normal control; One-way ANOVA followed by Dunnett test 
 
3.  FBS (Fasting blood glucose level): Fasting blood sugar level was determined by using glucose oxidase peroxidase reactive 
strips. 
Table 4: Effect of Glycyrrhizin on fasting blood glucose levels in rats. 
Sl. 
No. 
Treatment 
n=6 
Fasting blood glucose level (mg / dl) 
Day 0  Day  5  Day 10  Day 15  
1 Normal  97.14±1.53* 94.17±1.25 * 91.83± 1.01* 88.67±1.15 *  
2 Diabetic control 212.67±1.12 219.11± 0.88 227.83± 1.08 234.18± 1.31 
3 Standard  
(Glibenclamide,  
2.5mg/kg)  
210.33±1.45 180.55±0.76* 162.51±1.01* 133.67±1.14* 
4 Glycyrrhizin (50mg/kg)  211.14±1.83 197.33±1.33 175.83±1.34* 144.18±0.97* 
5 
Glycyrrhizin (100mg/kg)  
 215.67±0.65 185.65±1.50* 176.33±1.03* 146.52±1.08* 
Values expressed as mean ±S. E. M.; n = no. of animals in each group.  * p < 0.05 significant Vs diabetic control. One-way ANOVA 
followed by Dunnett test  
Preparation of polymeric microparticles: 
Microparticles were optimized on the basis of % 
entrapment, drug content and no. of particles formed. 
Optimized formula used for further work. Double emulsion 
method has been used in which polymer (chitosan) was 
dissolved in DMSO and emulsified into plant extract to form 
a emulsion. Primary emulsion then was subjected to the 
homogenization which results in formation of dispersion. 
The emulsion is then subjected to solvent removal either by 
solvent evaporation or by solvent extraction. Finally the 
microparticles were collected by filtration and are washed 
with demineralized water. 
 
Table 5: Optimization of Drug: polymer ratio 
Formulation code Ratio (Drug:Polymer) Average size(µm) No. of particles % Entrapment 
Ex-1 9:1 2.23±0.35 27±2.5 64.4±1.2 
Ex-2 8:2 2.34±0.54 28±2.2 68.8±0.98 
Ex-3* 7:3 2.29±0.57 36±1.9 70.5±1.10 
Ex-4 6:4 2.36±0.69 28±1.6 65.4±1.43 
Ex-5 5:5 2.15±0.14 23±1.5 64.8±0.85 
*Data are shown as mean   SD (n= 3) 
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Evaluation of polymeric microparticles: 
1. Particle Shape: Microparticles were visualized under 
Philips Morgani 268 Transmission Electron Microscope. 
A drop of the different formulations was placed on 
different carbon coated copper grids to leave a thin film 
on the grids. Then, the film was negatively stained with 
1% phosphotungastic acid (PTA) by placing a drop of the 
staining solution on to the film and the excess of the 
solution was drained off with a filter paper. The grid was 
allowed to dry thoroughly and formulations were viewed 
under a transmission electron microscope and 
photographs were taken at suitable magnification. 
 
Figure 3: SEM  
2. Particle size and distribution: The size and size 
distribution of vesicles was determined using laser 
diffraction particle size analyzer (Cilas, 1064 L, France). 
The microparticles suspension was dispersed in distilled 
water and then it was put into the sample chamber of 
particle size analyzer and measurement of vesicular size 
was carried out. 
3. Entrapment Efficiency: 1 g sephadex G-75 was allowed 
to swell in 10 ml of 0.9% NaCl solution in distilled water 
in a glass screw capped bottle for 5 hours at room 
temperature. The hydrated gel was filled to the top in the 
barrel of 1ml disposable syringe plugged with whatman 
filter pad. The barrel was then placed in the centrifuge 
tubes. The tubes were centrifuged at 2000 rpm for 3 
minutes to remove excess saline solution. Eluted saline 
was removed from the centrifuge tubes and exactly 0.2 
ml of suspension (undiluted) was applied dropwise on 
the top of the gel bed in the center. Columns were again 
centrifuged at 2000 rpm for 3 minutes to expel and 
remove void volume containing microparticles in to the 
centrifuge tubes. Elute was removed and 0.25 ml saline 
was applied to each column, and centrifuged as 
previously. The amount of drug entrapped in the vesicles 
was then determined by disrupting the vesicles followed 
by filtration and subsequent determination of the drug 
content using spectrophotometric method (Table 5). 
4. In-vitro drug release: 1 ml of pure suspension was 
placed in dialysis tube, which in turn was placed in a 
beaker containing 20 ml of PBS (7.4 pH). The solution 
containing the dialysis tube was stirred on a magnetic 
stirrer while keeping the temperature constant at 371°C 
throughout the study. Samples were withdrawn at 
different time intervals with subsequent analyzed for 
drug using Shimadzu 1601 UV spectrophotometer 
(Japan).   
 
 
Figure 4: Cumulative % Drug release 
CONCLUSION: 
Microparticles prepared by double emulsion technique to 
improve the drug release profile. In-vitro drug release 
studies shows that drug release controlled over prolong 
period of time, this will also decrease the dosing frequency of 
active constituent. Because of herbal origin thy side effects 
associated with synthetic drug also will less. 
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